These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7921445)

  • 1. Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma.
    Elias DJ; Kline LE; Robbins BA; Johnson HC; Pekny K; Benz M; Robb JA; Walker LE; Kosty M; Dillman RO
    Am J Respir Crit Care Med; 1994 Oct; 150(4):1114-22. PubMed ID: 7921445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma.
    Elias DJ; Hirschowitz L; Kline LE; Kroener JF; Dillman RO; Walker LE; Robb JA; Timms RM
    Cancer Res; 1990 Jul; 50(13):4154-9. PubMed ID: 2162255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer.
    Goodman GE; Hellström I; Brodzinsky L; Nicaise C; Kulander B; Hummel D; Hellström KE
    J Clin Oncol; 1990 Jun; 8(6):1083-92. PubMed ID: 2161448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
    Heist RS; Guarino MJ; Masters G; Purcell WT; Starodub AN; Horn L; Scheff RJ; Bardia A; Messersmith WA; Berlin J; Ocean AJ; Govindan SV; Maliakal P; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM; Camidge DR
    J Clin Oncol; 2017 Aug; 35(24):2790-2797. PubMed ID: 28548889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
    Ross HJ; Hart LL; Swanson PM; Rarick MU; Figlin RA; Jacobs AD; McCune DE; Rosenberg AH; Baron AD; Grove LE; Thorn MD; Miller DM; Drachman JG; Rudin CM
    Lung Cancer; 2006 Oct; 54(1):69-77. PubMed ID: 16934909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody.
    Stein R; Basu A; Chen S; Shih LB; Goldenberg DM
    Int J Cancer; 1993 Dec; 55(6):938-46. PubMed ID: 8253531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin.
    Desrues B; Léna H; Brichory F; Ramée MP; Toujas L; Delaval P; Dazord L
    Br J Cancer; 1995 Nov; 72(5):1076-82. PubMed ID: 7577450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigens associated with a human lung adenocarcinoma defined by monoclonal antibodies.
    Varki NM; Reisfeld RA; Walker LE
    Cancer Res; 1984 Feb; 44(2):681-7. PubMed ID: 6362852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
    Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G
    Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: specificity and tumor targeting.
    Stein R; Chen S; Sharkey RM; Goldenberg DM
    Cancer Res; 1990 Feb; 50(4):1330-6. PubMed ID: 2153458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
    Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
    Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production and characterization of a monoclonal antibody against an antigen on the surface of non-small cell carcinoma of the lung.
    Sharifzadeh S; Modjtahedi H; Jedi Tehrani M; Bayat A; Ghaderi A
    Iran J Immunol; 2007 Dec; 4(4):206-14. PubMed ID: 18057578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
    Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
    J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TROP2-Directed Antibody-Drug Conjugates in Advanced Non-Small Cell Lung Cancer: A Fading Hope?
    Pérol M
    J Clin Oncol; 2024 Aug; 42(24):2839-2842. PubMed ID: 38986037
    [No Abstract]   [Full Text] [Related]  

  • 20. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.